SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Xolair is a branded injectable medication used to treat allergic asthma, chronic hives, and rhinosinusitis. It’s recently been approved to manage food allergies, reducing the risk of serious reactions ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted, under ...
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed ...
If you or someone you know has a condition called chronic spontaneous urticaria (CSU), you may have heard about Xolair. In 2014, Xolair became the first medicine to be approved for treating this ...
Xolair is a brand-name prescription medication and is a biologic. Its active ingredient is called omalizumab. Generic versions of biologic medications are called biosimilars. Due to complex ...
Xolair is a brand-name prescription medication known as a biologic. Its active ingredient is omalizumab. Generic versions of biologic drugs are called biosimilars. Due to complex manufacturing ...
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...
A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. Data ...
Xolair (omalizumab) is a prescription drug that works by blocking IgE to help reduce inflammation. Your response to this drug may vary based on your medical history and diagnosis. IgE is a protein ...
Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. In this trial, we assessed whether omalizumab, a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results